Slashdot: Blocking a Key Enzyme May Reverse Memory Loss, MIT Study Finds

Blocking a Key Enzyme May Reverse Memory Loss, MIT Study Finds
Published on August 09, 2017 at 05:20PM
A better treatment for Alzheimer’s patients may be on the horizon thanks to new research from MIT. Researchers at MIT’s Picower Institute for Learning and Memory have discovered that they can reverse memory loss in mice by blocking an enzyme called HDAC2. From the study: For several years, scientists and pharmaceutical companies have been trying to develop drugs that block this enzyme, but most of these drugs also block other members of the HDAC family, which can lead to toxic side effects. The MIT team has now found a way to precisely target HDAC2, by blocking its interaction with a binding partner called Sp3. “This is exciting because for the first time we have found a specific mechanism by which HDAC2 regulates synaptic gene expression,” says Li-Huei Tsai, director of MIT’s Picower Institute for Learning and Memory and the study’s senior author. Blocking that mechanism could offer a new way to treat memory loss in Alzheimer’s patients. In this study, the researchers used a large protein fragment to interfere with HDAC-2, but they plan to seek smaller molecules that would be easier to deploy as drugs. Picower Institute postdocs Hidekuni Yamakawa, Jemmie Cheng, and Jay Penney are the lead authors of the study, which appears in the Aug. 8 edition of Cell Reports.